|Day Low/High||217.71 / 217.94|
|52 Wk Low/High||65.54 / 217.94|
Conference call and webcast on November 9 at 4:30 p.m. EST
AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, announced data as of August 7, 2017, from the...
The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 735,315 share decrease in total short interest for AveXis Inc , to 3,638,567, a decrease of 16.81% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
-- Conference call and webcast on August 10 at 4:30 p.m. EDT --
Six charts showing signs of smart money footprints.
AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.
REGENXBIO grants AveXis new licenses to NAV AAV9 vector for the development and commercialization of treatments for Rett syndrome (RTT) and amyotrophic lateral sclerosis (ALS)
Investors in AveXis Inc saw new options begin trading this week, for the July 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXS options chain for the new July 21st contracts and identified one put and one call contract of particular interest.
- Conference call of April 25 was in lieu of Q1 2017 earnings call -
Results to be reported on May 11, 2017
Investors focus on a drug's efficacy and safety. Much less time is spent considering the importance of manufacturing, even though it is a vital step in the drug approval process.
AveXis, Esperion Therapeutics, Medicines Co. and Amgen were among the biotech stock movers Friday morning.
These heavily shorted stocks could get squeezed higher if they report positive earnings this week.
In recent trading, shares of AveXis Inc have crossed above the average analyst 12-month target price of $68.50, changing hands for $68.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
-- Key preclinical and clinical data of AVXS-101 in SMA to be presented --
Here's how to rake in the gains off some potential major breakouts.
Company provides update following receipt of Scientific Advice response from the EMA
PRIME intended to optimize development and speed evaluation of AVXS-101 through enhanced interactions and early dialogue with EMA
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.